Researchers identify new potential mechanism for age-related macular degeneration
Using laboratory-grown roundworms as well as human and mouse eye tissue, University of Maryland School of Medicine (UMSOM) researchers have identified a new potential mechanism for age-related macular degeneration-;the leading cause of blindness among older adults.
The UMSOM researchers say that the findings suggest a new and distinct cause that is different from the previous model of a problematic immune system, showing that the structural organization of the eye s light-detecting cells may be affected by the disease.
The discovery offers the potential to identify new molecular targets to treat the disease. Their discovery was published on April 12 in the
Detroit Art Academy Gets $30 Million for DEI Efforts
philanthropy.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from philanthropy.com Daily Mail and Mail on Sunday newspapers.
Pixium Vision announces first patient successful implantation in Prima System pivotal trial PRIMAvera
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
April 7, 2021 GMT
SEATTLE, April 7, 2021 /PRNewswire/ LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry Age-Related Macular Degeneration (AMD) patients.
The prospective, double-masked, randomized, multi-center, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight leading retinal centers based in the United Kingdom, Germany, Spain, Italy and France. The objective was to treat dry AMD subjects over the course of three rounds of PBM sessions every four months with a duration of 10 months. The study was converted to a smaller pilot as some of th
LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
adnkronos.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adnkronos.com Daily Mail and Mail on Sunday newspapers.